Stage 2 is asymptomatic cerebral amyloidosis plus “downstream” neurodegeneration based on high CSF tau/P‐tau ratio, neuronal dysfunction, cortical thinning, and hippocampal atrophy. This evidence concerns the gene MAPT and hippocampal atrophy.